Work

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Year: 2020

Type: article

Study design: Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(20)30271-0

Authors: Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura, Yasutoshi Kuboki, Masashi Wakabayashi, Shogo Nomura, Yuichi Mikamoto, Hikari Shima, Noriko Fujishiro, Tsukiko Higuchi, Akihiro Sato, Takeshi Kuwata, Kohei Shitara

Institution: National Cancer Center Hospital East

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Eisai, Merck Sharp and Dohme

OpenAlex ID: W3036571927

FWCI: 20.78

Cites: 29

Cited by: 270

Related to: 10